Tacrolimus for the prevention and treatment of rejection of solid organ transplants
- 9 December 2015
- journal article
- review article
- Published by Taylor & Francis Ltd in Expert Review of Clinical Immunology
- Vol. 12 (3), 333-342
- https://doi.org/10.1586/1744666x.2016.1123093
Abstract
Since its introduction to the antirejection armamentarium in 1994, tacrolimus has become the workhorse of transplant professionals for avoidance of solid organ transplant rejection. Not only does tacrolimus have potent immunosuppressive qualities that prevent rejection, but dosing is straight forward and it is generally well tolerated. However, in the long term, conditions such as calcineurin inhibitor nephrotoxicity can become a problem. A discussion of the compound, the pharmacokinetics, history, and current approved uses for tacrolimus is described. Indeed, tacrolimus is the most important drug for preventing transplant rejection. However, the increased appreciation for significant side effects, particularly in the long term, has led to building interest in new agents with different mechanisms of action and different metabolism.Keywords
This publication has 55 references indexed in Scilit:
- Clinical Implications of Basic Science Discoveries: Induced Pluripotent Stem Cell Therapy in Transplantation—A Potential Role for Immunologic ToleranceAmerican Journal of Transplantation, 2015
- ToleranceTransplantation, 2014
- OPTN/SRTR 2012 Annual Data Report: KidneyAmerican Journal of Transplantation, 2014
- CTLA-4 on alloreactive CD4 T cells interacts with recipient CD80/86 to promote toleranceBlood, 2009
- Pancreas Transplant Alone as an Independent Risk Factor for the Development of Renal Failure: A Retrospective StudyTransplantation, 2008
- HLA-Mismatched Renal Transplantation without Maintenance ImmunosuppressionThe New England Journal of Medicine, 2008
- Improved Graft Survival after Renal Transplantation in the United States, 1988 to 1996The New England Journal of Medicine, 2000
- Cyclosporine: Five Years' Experience in Cadaveric Renal TransplantationThe New England Journal of Medicine, 1984
- Combined Immunosuppressive Action of Phytohaemagglutinin and Azathioprine (Imuran) on Dogs with Renal HomotransplantsBMJ, 1965
- Prolonged Survival of Human-Kidney Homografts by Immunosuppressive Drug TherapyThe New England Journal of Medicine, 1963